Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 1
2016 1
2017 5
2018 2
2019 2
2020 1
2021 2
2022 2
2023 1
2024 2
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
TOP1 Priority: Advancing Biomarker-Driven Patient Selection for the Use of ADCs.
Gwin WR 3rd, Hurvitz SA. Gwin WR 3rd, et al. Clin Cancer Res. 2025 May 15;31(10):1824-1826. doi: 10.1158/1078-0432.CCR-25-0166. Clin Cancer Res. 2025. PMID: 40095530
A recent study reports the emergence of TOP1 mutations as a potential mechanism of resistance to topoisomerase inhibitor antibody-drug conjugates (ADC) in advanced breast cancer. This is a crucial first step in identifying biomarkers to guide ADC therapy selection and unde …
A recent study reports the emergence of TOP1 mutations as a potential mechanism of resistance to topoisomerase inhibitor antibody-drug conju …
A Phase II Study of Denileukin Diftitox in Patients with Advanced Treatment Refractory Breast Cancer.
Gwin WR 3rd, Salazar LG, Dai JY, Higgins D, Coveler AL, Childs JS, Blancas R, Dang Y, Reichow J, Slota M, Lu H, Disis ML. Gwin WR 3rd, et al. Vaccines (Basel). 2025 Jan 24;13(2):117. doi: 10.3390/vaccines13020117. Vaccines (Basel). 2025. PMID: 40006664 Free PMC article.
This Phase II study aimed to assess the safety of denileukin diftitox and its effect on Tregs and tumor growth in patients with advanced breast cancer. Methods: This single-arm Phase II study of denileukin diftitox enrolled patients with refractory stage IV breast cance …
This Phase II study aimed to assess the safety of denileukin diftitox and its effect on Tregs and tumor growth in patients with advanced bre …
Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancer.
Hunter NB, Peterson LM, Specht JM, Mankoff DA, Muzi M, Chen DL, Gwin WR, Vinayak S, Davidson NE, Linden HM. Hunter NB, et al. Among authors: gwin wr. Breast Cancer Res. 2025 Feb 17;27(1):23. doi: 10.1186/s13058-025-01975-1. Breast Cancer Res. 2025. PMID: 39962532 Free PMC article.
BACKGROUND: (18)F-Fluorodeoxyglucose (FDG) and (18)F-Fluorestradiol (FES) have been FDA approved for measuring tumor glycolytic activity and estrogen receptor (ER) uptake, respectively, in clinical positron emission tomography (PET) imaging for patients with hormone-receptor (HR) …
BACKGROUND: (18)F-Fluorodeoxyglucose (FDG) and (18)F-Fluorestradiol (FES) have been FDA approved for measuring tumor glycolytic activity and …
Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer.
Liao JB, Jejurikar NS, Hitchcock-Bernhardt KM, Gwin WR, Reichow JL, Dang Y, Childs JS, Coveler AL, Swensen RE, Goff BA, Disis ML, Salazar LG. Liao JB, et al. Among authors: gwin wr. Gynecol Oncol. 2024 Dec;191:74-79. doi: 10.1016/j.ygyno.2024.09.019. Epub 2024 Oct 2. Gynecol Oncol. 2024. PMID: 39362046 Clinical Trial.
Regulatory T cells in the local immune microenvironment have been shown to be associated with poor prognosis in ovarian cancer. This study examined whether denileukin diftitox (ONTAK) could be safely administered intraperitoneal in patients with advanced refractory ovarian …
Regulatory T cells in the local immune microenvironment have been shown to be associated with poor prognosis in ovarian cancer. This …
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial.
Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Musolino A, Pegram MD, Bachelot T, Wright GS, Saura C, Escrivá-de-Romaní S, De Laurentiis M, Schwartz GN, Pluard TJ, Ricci F, Gwin WR 3rd, Levy C, Brown-Glaberman U, Ferrero JM, de Boer M, Kim SB, Petráková K, Yardley DA, Freedman O, Jakobsen EH, Gal-Yam EN, Yerushalmi R, Fasching PA, Kaufman PA, Ashley EJ, Perez-Olle R, Hong S, Rosales MK, Gradishar WJ; SOPHIA Study Group. Rugo HS, et al. Among authors: gwin wr 3rd. J Clin Oncol. 2023 Jan 10;41(2):198-205. doi: 10.1200/JCO.21.02937. Epub 2022 Nov 4. J Clin Oncol. 2023. PMID: 36332179 Free PMC article. Clinical Trial.
Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Final overall survival (OS) in SOPHIA (ClinicalTrials.gov identifier: NCT02492711), a study of ma …
Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the p …
Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
Abe S, Nagata H, Crosby EJ, Inoue Y, Kaneko K, Liu CX, Yang X, Wang T, Acharya CR, Agarwal P, Snyder J, Gwin W, Morse MA, Zhong P, Lyerly HK, Osada T. Abe S, et al. Among authors: gwin w. J Immunother Cancer. 2022 Jan;10(1):e003717. doi: 10.1136/jitc-2021-003717. J Immunother Cancer. 2022. PMID: 35039461 Free PMC article.
BACKGROUND: Despite multimodal adjuvant management with radiotherapy, chemotherapy and hormonal therapies, most surgically resected primary breast cancers relapse or metastasize. A potential solution to late and distant recurrence is to augment systemic antitumor immunity, …
BACKGROUND: Despite multimodal adjuvant management with radiotherapy, chemotherapy and hormonal therapies, most surgically resected primary …
Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates.
Liao JB, Gwin WR, Urban RR, Hitchcock-Bernhardt KM, Coveler AL, Higgins DM, Childs JS, Shakalia HN, Swensen RE, Stanton SE, Tinker AV, Wahl TA, Ancheta RG, McGonigle KF, Dai JY, Disis ML, Goff BA. Liao JB, et al. Among authors: gwin wr. J Immunother Cancer. 2021 Sep;9(9):e003122. doi: 10.1136/jitc-2021-003122. J Immunother Cancer. 2021. PMID: 34531249 Free PMC article.
BACKGROUND: Anti-programmed death 1 (PD1)/programmed cell death ligand 1 (PD-L1) therapies have shown modest activity as monotherapy in recurrent ovarian cancer. Platinum chemotherapies induce T-cell proliferation and enhance tumor recognition. We assessed activity and saf …
BACKGROUND: Anti-programmed death 1 (PD1)/programmed cell death ligand 1 (PD-L1) therapies have shown modest activity as monotherapy in recu …
Vaccine Therapies for Cancer: Then and Now.
Morse MA, Gwin WR 3rd, Mitchell DA. Morse MA, et al. Among authors: gwin wr 3rd. Target Oncol. 2021 Mar;16(2):121-152. doi: 10.1007/s11523-020-00788-w. Epub 2021 Jan 29. Target Oncol. 2021. PMID: 33512679 Free PMC article. Review.
Despite the historical track record, breakthrough advances in cancer immunobiology and vaccine technologies have supported continued interest in therapeutic cancer vaccinations, with the hope that next-generation vaccine strategies will enable patients with cance …
Despite the historical track record, breakthrough advances in cancer immunobiology and vaccine technologies have supported continued …
22 results